11/19/2019  11:02:54 AM Chg. +2.80 Volume Bid11:05:08 AM Ask11:05:14 AM Market Capitalization Dividend Y. P/E Ratio
299.80CHF +0.94% 20,650
Turnover: 3.84 mill.
299.60Bid Size: 796 299.80Ask Size: 175 258.18 bill.CHF 2.93% 24.17

Business description

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostics that enable tangible improvements in the health, quality of life and survival of patients. Founded in 1896, Roche has been making important contributions to global health for more than a century. Twenty-four medicines developed by Roche are included in the World Health Organisation Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and chemotherapy.

Management board & Supervisory board

Dr. Severin Schwan
Management board
Cristina A. Wilbur, Dr. Alan Hippe, Dr. Gottlieb Keller, Thomas Schinecker, William Anderson
Supervisory board
Dr. Christoph Franz, André Hoffmann, Anita Hauser, Bernard Poussot, Dr. Andreas Oeri, Dr. Claudia Süssmuth Dyckerhoff, Dr. Severin Schwan, Julie Brown, Paul Bulcke, Prof. Dr. Hans Clevers, Prof. Dr. Richard Lifton, Prof. John Irving Bell

Company data

Name: Roche Holding
Address: Grenzacherstraße 124,CH-4070 Basel
Phone: +41-61-688-1111
Fax: -
E-mail: basel.webmaster@roche.com
Internet: www.roche.com
Industry: Healthcare
Sector: Pharmaceutical Industry
Sub sector: Pharmaceuticals
End of financial year: 12/31
Free Float: 3.08%
IPO date: -

Investor relations

Name: Karl Mahler
IR phone: +41-61-687-8503
IR Fax: -
IR e-mail: investor.relations@roche.com

Company calendar

CW 5 | 1/30/2020 4th Quarter/Annual Report
CW 12 | 3/17/2020 General Shareholder Meeting
CW 17 | 4/22/2020 Interim Report 1st Quarter/3 Months
CW 30 | 7/23/2020 Interim Report 2nd Quarter/6 Months
CW 42 | 10/16/2020 Interim Report 3rd Quarter/9 Months

Main Shareholders

Aktionärsgruppe der Familien Hoffmann und Oeri-Hoffmann
Novartis Ltd
Maja Oeri